Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com

GILEAD SCIENCES, INC.

Statements
NotesSupport
aboutterms
2.2.0.25truefalse41302 - Disclosure - Segment Information (Product Sales) (Details)truefalseIn Thousandsfalse1falsefalseUSDfalsefalse1/1/2011 - 3/31/2011 USD ($) USD ($) / shares $Duration_1_1_2011_To_3_31_2011http://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.gilead.com/2011-03-31yearsgild0USDUSD$2falsefalseUSDfalsefalse1/1/2010 - 3/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_3_31_2010http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse18635780001863578falsetruefalsefalsefalse2truefalsefalse17880630001788063falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse3false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse4false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse16306900001630690falsefalsefalsefalsefalse2truefalsefalse15966370001596637falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse5false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse5falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Atripla [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_AtriplaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseAtripla [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AtriplaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Atripla [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_AtriplaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseAtripla [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AtriplaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse6false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse744512000744512falsefalsefalsefalsefalse2truefalsefalse692872000692872falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse7false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse7falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Truvada [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_TruvadaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseTruvada [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TruvadaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Truvada [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_TruvadaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseTruvada [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TruvadaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse8false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse673111000673111falsefalsefalsefalsefalse2truefalsefalse657799000657799falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse9falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Viread [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_VireadMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseViread [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_VireadMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Viread [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_VireadMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseViread [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_VireadMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse10false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse168395000168395falsefalsefalsefalsefalse2truefalsefalse180686000180686falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse11false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse11falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Hepsera [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_HepseraMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseHepsera [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_HepseraMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Hepsera [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_HepseraMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseHepsera [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_HepseraMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse12false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3809600038096falsefalsefalsefalsefalse2truefalsefalse5812400058124falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse13falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Emtriva [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_EmtrivaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseEmtriva [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_EmtrivaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_StatementScenarioAxis} : Antiviral Products [Member] {us-gaap_ProductOrServiceAxis} : Emtriva [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_EmtrivaMember_us-gaap_StatementScenarioAxis_gild_AntiviralProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAntiviral Products [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldigild_AntiviralProductsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseEmtriva [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_EmtrivaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse14false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse65760006576falsefalsefalsefalsefalse2truefalsefalse71560007156falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse15false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse15falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : AmBisome [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_AmbisomeMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseAmBisome [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AmbisomeMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : AmBisome [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_AmbisomeMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseAmBisome [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_AmbisomeMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse16false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse7850600078506falsefalsefalsefalsefalse2truefalsefalse7704900077049falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse17false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse17falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Letairis [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_LetairisMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseLetairis [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LetairisMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Letairis [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_LetairisMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseLetairis [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LetairisMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse18false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse6217400062174falsefalsefalsefalsefalse2truefalsefalse5549900055499falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse19false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse19falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Ranexa [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_RanexaMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseRanexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RanexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Ranexa [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_RanexaMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseRanexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RanexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse20false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse6829300068293falsefalsefalsefalsefalse2truefalsefalse5124300051243falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.gilead.com/taxonomy/role/disclosuresegmentinformationproductsalesdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse21falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Other Products [Member] 1/1/2011 - 3/31/2011 USD ($) $Duration_1_1_2011_To_3_31_2011_us-gaap_ProductOrServiceAxis_gild_OtherProductsMemberhttp://www.sec.gov/CIK0000882095duration2011-01-01T00:00:002011-03-31T00:00:00falsefalseOther Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_OtherProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Other Products [Member] 1/1/2010 - 3/31/2010 USD ($) $Duration_1_1_2010_To_3_31_2010_us-gaap_ProductOrServiceAxis_gild_OtherProductsMemberhttp://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-03-31T00:00:00falsefalseOther Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_OtherProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse22false0us-gaap_SalesRevenueGoodsNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2391500023915falsetruefalsefalsefalse2truefalsefalse76350007635falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 falsefalse221Segment Information (Product Sales) (Details) (USD $)ThousandsUnKnownUnKnownUnKnownfalsetrue